EMA Authorised: Rolcya (denosumab) — Sandoz GmbH

View source ↗

Summary

The EMA authorised Rolcya, a denosumab product by Sandoz GmbH, for osteoporosis including postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Rolcya (denosumab)

Snippet

Status: Authorised. Therapeutic area: Osteoporosis;Osteoporosis, Postmenopausal;Bone Resorption. MAH: Sandoz GmbH. Decision date: 27/11/2025